CHMP: label extension for GSK's Cervarix; recommendation for Behring’s IgG
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline's human papillomavirus vaccine, Cervarix is poised to win a line extension for preventing premalignant genital lesions, including vulvar and vaginal lesions. The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) gave the extension the green light at this month's meeting.